A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
PALISADE BIO, INC.
PALI
$265M
Mkt Cap
$1.95
-3.47%
PALISADE BIO, INC. (PALI) has a 5-year average return on invested capital (ROIC) of -99.3%. This is below average and may indicate limited pricing power.
PALISADE BIO, INC. (PALI) has a market capitalization of $109M. It is classified as a small-cap stock.
PALISADE BIO, INC. (PALI) does not currently pay a regular dividend.
PALISADE BIO, INC. (PALI) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
PALISADE BIO, INC. (PALI) generated $-12 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PALISADE BIO, INC. (PALI) has a debt-to-equity ratio of 0.07. This indicates a conservatively financed balance sheet.
PALISADE BIO, INC. (PALI) reported earnings per share (EPS) of $-0.11 in its most recent fiscal year.
Company Overview We are a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. Our lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (“IBD”), including ulcerative colitis (“UC”) and Fibrostenotic Crohn’s disease (“FSCD”). Our Strategy Our objective is to establish ourselves as a leader in the development of differentiated product candidates targeting the autoimmune, inflammatory, and fibrotic disease markets, which we believe will address a large, well-established need among patients living with autoimmune and inflammatory diseases.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 250K | 0 | - | - |
| Net Income | -17M | -14M | - | - | -16M | -8.4M |
| EPS | $-1.56 | $-0.11 | $-3.94 | $-40.98 | $-5,265.00 | $-17,100.00 |
| Free Cash Flow | 0 | -12M | -11M | -13M | -9.0M | -7.3M |
| ROIC | -10.6% | -107.9% | - | - | -86.3% | -103.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.07 | 0.05 | 0.03 | 0.34 | 0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -18M | -15M | -13M | -16M | -11M | -8.6M |
| Operating Margin | 0.0% | - | -5228.0% | - | - | - |
| ROE | -13.0% | -153.6% | - | - | -218.4% | -162.9% |
| Shares Outstanding | 56M | 136M | 4M | 1M | 0M | 0M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 260K | N/A | N/A | 0 | 250K | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 6.1M | 7.3M | 8.4M | 13M | 13M | 8.1M | 4.0M | 4.1M | 2.0M | 6.5M | 6.9M | 16M | 10M |
| SG&A | 256K | 5.3M | 9.1M | 6.5M | 7.5M | 5.5M | 4.6M | 4.6M | 8.7M | 8.8M | 6.2M | 5.8M | 7.9M |
| EBIT | -10M | -13M | -17M | -19M | -21M | -13M | -8.3M | -8.6M | -11M | -16M | -13M | -15M | -18M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | -3176.7% | N/A | N/A | N/A | -5228.0% | N/A | 0.0% |
| Net Income | -10M | -20M | -23M | -21M | -21M | -16M | N/A | -8.4M | -16M | N/A | N/A | -14M | -17M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 1.0M | -10K | -8K | 0 | 0 | 0 | 410K | 225K | -4K | -4K |
| Returns on Capital | |||||||||||||
| ROIC | -91.7% | -195.1% | -115.7% | -122.5% | -72.1% | N/M | N/A | -103.6% | -86.3% | N/A | N/A | -107.9% | -10.6% |
| ROE | -234.5% | -257.7% | -173.2% | -184.3% | -258.6% | -157.9% | N/A | -162.9% | -218.4% | N/A | N/A | -153.6% | -13.0% |
| ROA | -157.7% | -140.8% | -91.9% | -93.3% | -112.2% | -85.9% | N/A | -126.8% | -165.7% | N/A | N/A | -115.8% | -12.5% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -8.5M | -11M | -12M | -19M | -16M | -13M | -7.7M | -7.3M | -9.0M | -13M | -11M | -12M | -11M |
| Free Cash Flow | -8.5M | -11M | -12M | -19M | -16M | -13M | -7.7M | -7.3M | -9.0M | -13M | -11M | -12M | 0 |
| Owner Earnings | -11M | -13M | -17M | -23M | -20M | -16M | -8.5M | -8.3M | -9.7M | -14M | -12M | -13M | -15M |
| CapEx | 39K | 125K | 208K | 176K | 98K | 11K | 2K | 2K | 0 | 10K | 4K | 0 | 0 |
| Maint. CapEx | 424K | 346K | 483K | 629K | 725K | 822K | 186K | 144K | 92K | 3K | 4K | 3K | 3K |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | N/A | 7K | 0 | N/A | 0 |
| D&A | 424K | 346K | 483K | 629K | 725K | 822K | 186K | 144K | 92K | 3K | 4K | 3K | 3K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.6M | 2.3M | 4.3M | 3.0M | 3.4M | 1.8M | 634K | 881K | 585K | 1.0M | 624K | 652K | 4.0M |
| Debt Repayment | 0 | 0 | 1.9M | 1.2M | 4.6M | 3.8M | 363K | 378K | 232K | 790K | 391K | 426K | 426K |
| Balance Sheet | |||||||||||||
| Net Debt | -7.4M | -9.0M | -19M | -4.2M | -16M | -11M | -11M | -10.0M | N/A | -12M | -12M | -9.3M | -133M |
| Cash & Equiv. | 7.4M | 17M | 13M | 4.7M | 15M | 6.7M | 5.8M | 5.1M | 11M | 12M | 12M | 9.8M | 133M |
| Long-Term Debt | 0 | 4.9M | 8.1M | 3.4M | 18K | 2K | N/A | N/A | N/A | N/A | N/A | N/A | 320K |
| Debt/Equity | 0.01 | 0.94 | 0.51 | 1.62 | 0.34 | 0.04 | 0.04 | 0.05 | 0.34 | 0.03 | 0.05 | 0.07 | 0.00 |
| Interest Coverage | -3763.0 | -9.0 | -10.8 | -10.5 | -18.1 | -83.7 | -1072.9 | -967.7 | -761.7 | -1209.3 | -871.3 | -1238.3 | -1238.3 |
| Equity | 7.0M | 8.4M | 18M | 5.0M | 11M | 8.5M | 6.0M | 5.1M | 9.8M | 12M | 11M | 7.5M | 129M |
| Total Assets | 8.8M | 19M | 30M | 15M | 23M | 14M | 7.7M | 6.6M | 13M | 16M | 14M | 11M | 134M |
| Total Liabilities | 1.8M | 11M | 12M | 10.0M | 11M | 5.4M | 1.6M | 1.5M | 3.3M | 3.3M | 2.7M | 3.4M | 5.0M |
| Intangibles | 807K | 1.1M | 1.2M | 1.1M | 990K | 883K | 1.5M | 1.3M | 294K | N/A | N/A | N/A | N/A |
| Retained Earnings | -109M | -128M | -151M | -172M | -193M | -209M | -214M | -222M | -238M | 109M | 122M | 136M | 136M |
| Working Capital | 5.9M | 12M | 24M | 7.0M | 14M | 11M | 5.5M | 4.4M | 9.7M | 12M | 11M | 7.3M | 130M |
| Current Assets | 7.7M | 18M | 28M | 13M | 21M | 12M | 6.5M | 5.6M | 13M | 15M | 13M | 10M | 134M |
| Current Liabilities | 1.8M | 5.9M | 4.0M | 6.4M | 7.3M | 1.5M | 1.1M | 1.2M | 3.2M | 3.0M | 2.6M | 3.2M | 4.6M |
| Per Share Data | |||||||||||||
| EPS | -1.32 | -2.09 | -2.01 | -23.16 | -19.60 | -0.93 | -33,930.00 | -17,100.00 | -5,265.00 | -40.98 | -3.94 | -0.11 | -1.56 |
| Owner EPS | -1.37 | -1.40 | -1.47 | -24.95 | -18.40 | -0.95 | -4,062.93 | -2,154.38 | -3,140.32 | -12.12 | -2.78 | -0.09 | -0.27 |
| Book Value | 0.91 | 0.89 | 1.58 | 5.50 | 10.54 | 0.51 | 2,887.46 | 1,333.68 | 3,161.53 | 10.51 | 2.67 | 0.06 | 2.32 |
| Cash Flow/Share | -1.10 | -1.12 | -1.04 | -20.98 | -14.52 | -0.80 | -3,671.60 | -1,887.78 | -2,921.12 | -11.25 | -2.63 | -0.09 | -0.30 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 7.7M | 9.5M | 11.2M | 0.9M | 1.1M | 16.9M | 0.0M | 0.0M | 0.0M | 1.2M | 4.2M | 136.0M | 55.7M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 9.4 | 23.4 | 13.5 | 19.4 | 2.9 | 2.7 | 10.0 | 3.1 | 1.2 | 1.9 | 3.8 | 0.3 | 0.8 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | 934.8 | N/A | N/A | N/A | 389.5 | N/A | N/A |
| FCF Yield | -13.0% | -5.4% | -5.0% | -19.8% | -48.4% | -58.1% | -12.8% | -46.1% | -74.6% | -57.8% | -26.0% | -515.3% | N/A |
| Market Cap | 65M | 197M | 239M | 96M | 32M | 23M | 60M | 16M | 12M | 23M | 43M | 2.4M | 109M |
| Avg. Price | 1,187,619.92 | 1,994,246.43 | 4,041,953.78 | 2,259,446.43 | 549,021.34 | 290,493.68 | 116,007.14 | 24,609.46 | 3,528.04 | 399.90 | 22.15 | 4.74 | 1.95 |
| Year-End Price | 1,287,000.00 | 3,135,600.00 | 3,217,500.00 | 1,240,200.00 | 351,000.00 | 159,300.00 | 28,800.00 | 4,095.00 | 3,915.00 | 27.15 | 9.75 | 1.67 | 1.95 |
PALISADE BIO, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
PALISADE BIO, INC. (PALI) has a return on equity (ROE) of -153.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 14 years of financial data for PALISADE BIO, INC. (PALI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PALISADE BIO, INC. (PALI) has a book value per share of $0.06, based on its most recent annual SEC filing.